Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma
Clinical trial NCT04756401 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04756401
- Sponsor
- Academic and Community Cancer Research United
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-08
- Primary completion
- 2024-09-30
- Enrollment
- 52
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.